Navigation Links
Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Date:11/5/2012

PARIS and TARRYTOWN, N.Y., Nov. 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ODYSSEY OUTCOMES trial, a Phase 3 cardiovascular outcomes trial (CVOT) with SAR236553/REGN727 is now recruiting patients.  SAR236553/REGN727 is an investigational subcutaneously administered, fully-human antibody that is being evaluated for its impact on lowering low-density lipoprotein cholesterol (LDL-C) by targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

The ODYSSEY OUTCOMES trial will enroll approximately 18,000 patients, who recently suffered an acute coronary syndrome (ACS), from 49 countries across six continents.  With the start of this study, eleven trials are now recruiting in the global SAR236553/REGN727 Phase 3 program.

"Despite widespread use of statin therapy, many patients at risk do not reach recommended targets for LDL.  Even among those who do reach targets, further LDL lowering may further reduce the risks of coronary heart disease (CHD) death, myocardial infarction (MI) and stroke," said Ph. Gabriel Steg M.D., Professor of Cardiology at the Hopital Bichat-Claude Bernard in Paris, France, and co-Chair of the ODYSSEY OUTCOMES Steering Committee.  "The ODYSSEY cardiovascular (CV) outcomes trial will test the efficacy and safety of SAR236553/REGN727 added to maximal doses of statins in reducing cardiovascular morbidity and mortality in patients with recent ACS, a population at high risk of CV events despite best contemporary therapy."

ODYSSEY OUTCOMES is a double-blind, randomized, placebo-controlled, multi-national study.  The primary objective of the study is to evaluate the effect of SAR236553/REGN727 on the incidence of cardiovascular events in patien
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
6. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
7. Regeneron Announces June 2012 Investor Conference Presentations
8. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
9. Regeneron Announces September 2012 Investor Conference Presentations
10. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
11. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Physician E-sampling is becoming well established across ... key marketing sales tactic in recent years. However, some ... a supplement to traditional sampling. According ... E-sampling has been seeded across multiple therapeutic areas- including ... has been in place for five or more years ...
(Date:9/4/2015)...  Janssen Research & Development, LLC (Janssen) announced ... has accepted for Priority Review the Biologics License ... patients with multiple myeloma who are refractory to ... agent (IMiD), or who have received three or ... and an IMiD. This is referred to as ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
Breaking Medicine Technology:Current and Future Trends in Physician E-Sampling Programs for the Pharmaceutical Industry 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3
(Date:9/4/2015)... Dallas, TX (PRWEB) , ... September 04, 2015 , ... ... in Iraq in 2007, will compete in the Ironman World Championships in Kona on ... veterans who have incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments ...
(Date:9/4/2015)... ... 2015 , ... The conference program for the upcoming Integrative ... 2015 at the Diplomat Resort & Spa has been announced and is available ... the top of their field and will be presenting sessions such as What ...
(Date:9/4/2015)... ... September 04, 2015 , ... Steven Winter Associates, Inc., (SWA) ... been selected for the Residential Award of Merit by the Connecticut Green Building ... from a highly competitive field of submissions, the net-zero energy residence will be ...
(Date:9/4/2015)... Florida (PRWEB) , ... September 04, 2015 , ... ... ambulance and medical assistance company today announced that it has entered into a ... week, EMED signed an agreement to bridge the link between American healthcare, Jamaican ...
(Date:9/3/2015)... ... September 03, 2015 , ... Allied Anesthesia is proud to announce a ... norm not the exception. , St. Jude was recently named one of the nation’s ... making it one of only 10 hospitals in the state to earn the distinction. ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3
... found those with more of the male hormone in the ... -- New research out of Britain finds that financial traders ... testosterone tend to make more money that day, probably because ... traders with higher levels of the stress hormone cortisol tend ...
... ELMWOOD PARK, N.J. and NEW YORK, April 14 ,HLTH Corporation ... Health Corp. (Nasdaq: WBMD ), today announced that they ... March 31,2008 at approximately 4:00 pm (ET) on Tuesday, May ... pm (ET) on that day to discuss those,results., Investors ...
... macular degeneration, study finds , , MONDAY, April 14 (HealthDay ... lower risk of developing advanced age-related macular degeneration, especially ... a U.S. study finds. , Age-related macular degeneration (AMD) ... of vision loss and blindness among older adults, according ...
... sufferers, the Medicare Prescription Drug Improvement and Modernization ... management with biologic drugs. Prior to its passage ... tumor necrosis factor (TNF) inhibitors, the infusion ... Remicade. Since the MMA, most Medicare prescription drug ...
... Managed Market Teams Choose Best Plans for ... 14 Qforma, an advanced analytics,company, today ... Care,Optimization model. This innovative new tool was ... informed contracting and,pull-through strategies. iQMCO(TM) utilizes advanced ...
... exercise outside organized teams has drops as adolescence approaches, ... A record number of American girls are participating in ... sports are decreasing, especially as they go from childhood ... from the University of Minnesota Tucker Center for Research ...
Cached Medicine News:Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Hormone Replacement May Cut Risk for Age-Linked Eye Disease 2Health News:Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients 2Health News:Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients 3Health News:Qforma Unveils Managed Care Optimization Solution for Pharma Marketing Executives 2Health News:Girls Participating in Sports in Record Numbers 2
...
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Medicine Products: